^
    Back
    Association details:
    Biomarker:HER-2 Y772_A775dup
    Cancer:Non Small Cell Lung Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JTO Clin Res Rep
    Title:

    Successful Rechallenge of Trastuzumab Deruxtecan After Drug-induced Interstitial Lung Disease in a Non-Small Cell Lung Cancer with HER2 mutation: A Case Report

    Published date:
    12/26/2023
    Excerpt:
    We report a case of successful rechallenge of trastuzumab deruxtecan after recovery of grade 3 ILD/pneumonitis in treatment-refractory NSCLC harboring ERBB2 Y772-A775dup.
    DOI:
    https://doi.org/10.1016/j.jtocrr.2023.100628